We expect the company will have generated revenues of roughly $4 billion in 2025, with Invisalign accounting for over $3 ...
Nuvation Bio earns a modest Buy at ~$5, supported by the steady adoption of IBTROZI, its lead asset, by patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results